{"id":"W2002698748","doi":"10.1016/j.cjca.2014.07.493","title":"APIXABAN FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS: DATA FROM THE AMPLIFY TRIAL","year":2014,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"","keywords":"Medicine; Apixaban; Coronary angiography; Venous thromboembolism; Nephrotoxicity; Internal medicine; Computed tomographic angiography; Cardiology; Angiography; Intensive care medicine; Radiology; Thrombosis; Kidney; Myocardial infarction; Rivaroxaban","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001737623,0.0008685188,0.002518096,0.000207955,0.0002439507,0.001392086,0.0004737441,0.0009301295,0.002899534],"category_scores_gemma":[0.005012643,0.0002866187,0.002242114,0.0005077861,0.0004205163,0.0008516962,0.000404365,0.002580029,0.0004479928],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004492966,"about_ca_system_score_gemma":0.0006628108,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007885203,"about_ca_topic_score_gemma":0.001894784,"domain_scores_codex":[0.9988655,0.0006629381,0.0001024483,0.0001293057,0.0001369528,0.0001029862],"domain_scores_gemma":[0.9979309,0.0009803904,0.0005155653,0.0001914068,0.0001270374,0.0002547085],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8726668,0.001038077,0.0194094,0.005323349,0.01844426,0.0003319886,0.0001401573,0.001810995,0.003283103,0.001170711,0.01358766,0.06279355],"study_design_scores_gemma":[0.8059875,0.03093361,0.0993836,0.0008630991,0.03634346,0.0009811288,0.0002226846,0.002282375,0.001764666,0.002303435,0.01879007,0.0001444081],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9115578,0.06856839,0.0006837081,0.003873553,0.0006179397,0.0004706894,0.006461927,0.00009650821,0.00766939],"genre_scores_gemma":[0.9710075,0.01883357,0.0006766442,0.001544653,0.0007173886,0.0004136523,0.005223018,0.00002992255,0.001553521],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002899534,"threshold_uncertainty_score":0.009699881,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06739652595232445,"score_gpt":0.3200632351959416,"score_spread":0.2526667092436171,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}